tasisulam (CHEBI:231621)

ChEBI > Main

Main

ChEBI Ontology

Automatic Xrefs

Reactions

Pathways

Models

ChEBI Name	tasisulam

ChEBI ID	CHEBI:231621

Definition	A thiophene substituted by a 2,4-dichlorobenzamide-N-sulfonyl and bromo groups at positions 2 and 4, respectively. It induces tumour cell apoptosis via ROS induction and mitochondrial membrane potential loss and currently in clinical development for the treatment of cancer.

Stars	This entity has been manually annotated by the ChEBI Team.

Submitter	Alexandra Millett

Supplier Information

Download	Molfile XML SDF

Formula

C11H6BrCl2NO3S2

Net Charge

Average Mass

415.100

Monoisotopic Mass

412.83495

InChI

InChI=1S/C11H6BrCl2NO3S2/c12-9-3-4-10(19-9)20(17,18)15-11(16)7-2-1-6(13)5-8(7)14/h1-5H,(H,15,16)

InChIKey

WWONFUQGBVOKOF-UHFFFAOYSA-N

SMILES

ClC1=CC=C(C(=O)NS(=O)(=O)C2=CC=C(Br)S2)C(Cl)=C1

Roles Classification
Biological Role(s):	apoptosis inducer Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.

Application(s):	angiogenesis inhibitor An agent and endogenous substances that antagonize or inhibit the development of new blood vessels. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms.

ChEBI Ontology
Outgoing	tasisulam (CHEBI:231621) has role angiogenesis inhibitor (CHEBI:48422) tasisulam (CHEBI:231621) has role antineoplastic agent (CHEBI:35610) tasisulam (CHEBI:231621) has role apoptosis inducer (CHEBI:68495) tasisulam (CHEBI:231621) is a N-sulfonylcarboxamide (CHEBI:90852) tasisulam (CHEBI:231621) is a dichlorobenzene (CHEBI:23697) tasisulam (CHEBI:231621) is a organobromine compound (CHEBI:37141) tasisulam (CHEBI:231621) is a thiophenes (CHEBI:26961)

IUPAC Name

N-[(5-bromothiophen-2-yl)sulfonyl]-2,4-dichlorobenzamide

Synonyms	Sources
LY 573636	ChEBI
LY-573636	ChEBI
LY573636	ChEBI
N-(2,4-dichlorobenzoyl)-5-bromothiophene-2-sulfonamide	SUBMITTER
N-(5-bromothiophen-2-yl)sulfonyl-2,4-dichlorobenzamide	SUBMITTER

Registry Number	Type	Source
519055-62-0	CAS Registry Number	DrugBank

Last Modified

28 June 2024